Drug Profile


Alternative Names: Maxy-G34; Maxy-GCSF; PEG-MAXY-G34; pegylated-MAXY-G34

Latest Information Update: 07 Jun 2013

Price : $50

At a glance

  • Originator Maxygen
  • Class Chemoprotectants; Granulocyte colony-stimulating factors
  • Mechanism of Action Granulocyte colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Neutropenia

Most Recent Events

  • 07 Jun 2013 Discontinued - Phase-II for Neutropenia in Ukraine (SC)
  • 07 Jun 2013 Discontinued - Phase-II for Neutropenia in Russia (SC)
  • 07 Jun 2013 Discontinued - Phase-II for Neutropenia in Romania (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top